Interferon alpha/beta receptor 1 Antibody (YA3833)

製品番号: HY-P84136: データシート SDS COA User Guide for Antibodies
FAQs
Technical Support

Interferon alpha/beta receptor 1 Antibody (YA3833) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Interferon alpha/beta receptor 1.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

容量	価格（税別）	在庫状況	数量
10 μL	$96	在庫あり	Estimated Time of Arrival: December 31
50 μL	$252	在庫あり	Estimated Time of Arrival: December 31
100 μL	$408	在庫あり	Estimated Time of Arrival: December 31
250 μL		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
説明
参考文献

製品説明

Interferon alpha/beta receptor 1 Antibody (YA3833) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Interferon alpha/beta receptor 1.

Host

Mouse

Clonality

Monoclonal Antibody

分子量

Predicted band size: 64 kDa;

Observed band size: 110-130 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Mouse

SwissProt ID

P17181

Gene ID

3454 [NCBI]

Immunogen

Purified recombinant fragment of human IFNAR1 (AA: 28-156) expressed in E. Coli.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-1:2000
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:200-1:1000
FC FC: Flow Cytometry	1:200-1:400
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:10000

純度	affinity purified.	Conjugation	Non-conjugated
Modification	Unmodified	Isotype	IgG1

Appearance

Liquid

Formulation

Supplied in PBS with 0.05% sodium azide

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

輸送条件

Shipping with blue ice.

Background

Function：Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa) (PubMed:10049744, PubMed:14532120, PubMed:15337770, PubMed:2153461, PubMed:21854986, PubMed:24075985, PubMed:31270247, PubMed:33252644, PubMed:35442418, PubMed:7813427). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response (PubMed:10049744, PubMed:21854986, PubMed:7665574). Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another (PubMed:21854986, PubMed:32972995, PubMed:7665574, PubMed:7813427). The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (PubMed:21854986, PubMed:32972995, PubMed:7526154, PubMed:7665574, PubMed:7813427). STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes (PubMed:19561067, PubMed:21854986, PubMed:32972995, PubMed:7665574, PubMed:7813427, PubMed:9121453). Can also act independently of IFNAR2: form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity)

Subcellular Localization：Cell membrane; Single-pass type I membrane protein; Late endosome; Lysosome

Expression：
Tissue_specificity:Interferon receptors are present in all tissues, even on the surface of most interferon-resistant cells. Isomers 1, 2, and 3 are expressed in the interferon-α-sensitive myeloma cell line U266B1. Isomers 2 and 3 are expressed in the interferon-α-resistant myeloma cell line U266R. Isomer 1 is not expressed in the interferon-α-resistant myeloma cell line U266R.

Isoforms & Post-Translational Modification：P17181 has 4 isomers: P17181-1: 63525 Da (predicted); P17181-2: 49547 Da (predicted); P17181-3: 56718 Da (predicted); P17181-4: 56046 Da (predicted).
Ubiquitinated, leading to its internalization and degradation (PubMed:14532120, PubMed:15337770). Polyubiquitinated via 'Lys-48'-linked and 'Lys-63'-linked ubiquitin chains, leading to receptor internalization and lysosomal degradation (PubMed:18056411). The 'Lys-63'-linked ubiquitin chains are cleaved off by the BRISC complex (PubMed:24075985);Phosphorylated on tyrosine residues in response to interferon-binding: phosphorylation by TYK2 tyrosine kinase creates docking sites for STAT proteins (PubMed:10049744, PubMed:7526154). Phosphorylated on serine residues in response to interferon binding; this promotes interaction with FBXW11 and ubiquitination (PubMed:14532120, PubMed:15337770, PubMed:24075985);Palmitoylation at Cys-463 is required for the activation of STAT1 and STAT2

Subunit：Heterodimer with IFNAR2; forming the receptor for type I interferon (PubMed:10049744, PubMed:21854986, PubMed:7665574). Interacts with TYK2 (PubMed:15337770, PubMed:24704786, PubMed:7526154). Interacts with STAT1 and STAT2; the interaction requires its phosphorylation at Tyr-466 (PubMed:9121453). Interacts (serine-phosphorylated form) with FBXW11, the substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex (PubMed:14532120, PubMed:15337770, PubMed:18056411). Interacts with SHMT2; this promotes interaction with ABRAXAS2 and the BRISC complex (PubMed:24075985). Interacts with TRIM10; this interaction prevents association between IFNAR1 and TYK2 (PubMed:33811647)

RRID

AB_3718844

Synonyms

AVP; IFRC; IFNAR; IFNBR; IFN-alpha-REC

ドキュメンテーション

Select Batch:

データシート (235 KB) SDS (252 KB)

COA (205 KB)

User Guide for Antibodies (1077 KB)

参考文献

[1]. /biology-dictionary/sf9-cell.html [Content Brief]